Farxiga 10 mg is a once-daily tablet with four FDA-approved uses: managing type 2 diabetes, treating heart failure, slowing chronic kidney disease, and reducing cardiovascular risk in people with type 2 diabetes who have heart disease. It belongs to a class of medications called SGLT2 inhibitors, which work by changing how your kidneys handle sugar and sodium. Originally developed as a diabetes drug, Farxiga’s uses have expanded significantly as clinical trials revealed benefits for the heart and kidneys that go well beyond blood sugar control.
How Farxiga Works in the Body
Your kidneys normally filter blood sugar out and then reabsorb most of it back into your bloodstream. Farxiga blocks the protein responsible for that reabsorption, so more glucose passes into your urine instead of cycling back into your blood. This lowers blood sugar without relying on insulin.
The same mechanism also changes how your kidneys handle sodium. By blocking sodium reabsorption alongside glucose, Farxiga reduces pressure inside the kidney’s filtering units. That pressure reduction is a key reason the drug protects kidney function over time and helps remove excess fluid from the body, which eases the workload on the heart.
Type 2 Diabetes
For blood sugar management, Farxiga is typically started at 5 mg and increased to 10 mg if more control is needed. In clinical trials, the 10 mg dose lowered A1c (a measure of average blood sugar over roughly three months) by about 0.8 to 0.9 percentage points when added to other common diabetes medications. When combined with metformin from the start, the reduction was closer to 2.0 percentage points.
Beyond blood sugar, people taking Farxiga 10 mg in trials lost an average of about 6 pounds over 24 weeks, whether they took it alone or alongside metformin. That weight loss is a direct consequence of the extra calories leaving the body through urine as glucose. It’s a modest but consistent effect that distinguishes SGLT2 inhibitors from several other diabetes drug classes, some of which cause weight gain.
Heart Failure
Farxiga is approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure, regardless of whether they also have diabetes. The landmark DAPA-HF trial, which enrolled patients with heart failure and reduced pumping ability, found that adding Farxiga 10 mg to standard treatment lowered the combined rate of cardiovascular death, heart failure hospitalization, or urgent heart failure visits from 21.2% in the placebo group to 16.3% in the Farxiga group. Heart failure hospitalizations specifically dropped from 13.4% to 9.7%.
The benefit likely comes from Farxiga’s ability to reduce fluid retention and lower the pressure the heart has to pump against. For patients, this can translate to less shortness of breath, less swelling, and fewer emergency hospital visits.
Chronic Kidney Disease
Farxiga 10 mg is approved to slow the progression of chronic kidney disease (CKD) in adults at risk of worsening, with or without diabetes. The DAPA-CKD trial followed over 4,300 patients with CKD stages 2 through 4 for a median of about 28.5 months. Farxiga reduced the combined risk of significant kidney function decline, end-stage kidney disease, or death from kidney or cardiovascular causes by 39% compared to placebo. In absolute terms, 5.3% fewer patients experienced these outcomes.
This was a landmark finding because it showed kidney protection in patients who didn’t have diabetes at all, not just those who did. It fundamentally changed how the drug is used in clinical practice.
Cardiovascular Risk Reduction in Diabetes
Farxiga also carries a separate approval specifically to reduce heart failure hospitalizations in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. This use targets people who may not yet have heart failure but are at high risk for it due to conditions like prior heart attack, peripheral artery disease, or a combination of factors like high blood pressure, smoking, and high cholesterol.
Why 10 mg Is the Standard Dose for Most Uses
The 5 mg dose exists only as a starting point for blood sugar management. For heart failure, chronic kidney disease, and cardiovascular risk reduction, 10 mg is both the starting and the recommended dose. If you’ve been prescribed 10 mg, it may be for any one of these four indications, or your prescriber may be targeting more than one benefit at once, since the drug’s effects on blood sugar, the heart, and the kidneys happen simultaneously.
Common Side Effects
Because Farxiga pushes extra sugar into the urine, it creates an environment where yeast can thrive. Genital yeast infections are the most common side effect, particularly in women. Urinary tract infections also occur more frequently than with placebo in clinical trials. Both are generally mild and treatable.
The fluid loss that benefits heart failure patients can sometimes cause dehydration, dizziness, or lightheadedness, especially in older adults or those already taking diuretics. Staying well hydrated matters more on this medication than it might otherwise.
A rarer but serious concern is a form of diabetic ketoacidosis where blood sugar levels remain only moderately elevated rather than very high, making it easy to miss. Symptoms include rapid weight loss, nausea or vomiting, stomach pain, unusually deep or fast breathing, and a sweet or metallic taste in the mouth. The risk increases during illness, dehydration, surgery, heavy alcohol use, or if insulin doses are suddenly reduced. This side effect is uncommon, but recognizing the symptoms early is important because the normal blood sugar readings can be misleading.